Should I buy or sell Unity Biotechnology stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UBX shares. View UBX analyst ratings or view top-rated stocks .

What is Unity Biotechnology's stock price target for 2024?

2 brokerages have issued twelve-month target prices for Unity Biotechnology's stock. Their UBX share price targets range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 297.4% from the stock's current price. View analysts price targets for UBX or view top-rated stocks among Wall Street analysts .

How have UBX shares performed in 2024?

Unity Biotechnology's stock was trading at $1.93 at the beginning of 2024. Since then, UBX stock has decreased by 21.8% and is now trading at $1.51. View the best growth stocks for 2024 here .

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our UBX earnings forecast .

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its earnings results on Wednesday, November, 10th. The company reported ($3.00) earnings per share for the quarter, topping analysts' consensus estimates of ($3.60) by $0.60.

When did Unity Biotechnology's stock split?

Unity Biotechnology shares reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO) , Inseego (INSG) , NVIDIA (NVDA) , Editas Medicine (EDIT) , Advanced Micro Devices (AMD) , VBI Vaccines (VBIV) , Enphase Energy (ENPH) , Sorrento Therapeutics (SRNE) and OPKO Health (OPK) .

When did Unity Biotechnology IPO?

Unity Biotechnology (UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:UBX

Unity Biotechnology (UBX) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free UBX Stock Alerts

$1.51

+0.01 (+0.67%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.50
▼
$1.54
50-Day Range: $1.50
▼
$1.99
52-Week Range: $1.50
▼
$3.82

Volume: 27,572 shs
Average Volume: 87,545 shs
Market Capitalization: $25.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get Unity Biotechnology alerts:

Unity Biotechnology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 297.4% Upside
$6.00 Price Target
Short Interest: Healthy
2.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.60
Upright™ Environmental Score
News Sentiment: 0.30
Based on 9 Articles This Week
Insider Trading: Selling Shares
$2,023 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.66) to ($1.98) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.06 out of 5 stars

Medical Sector

162nd out of 918 stocks

Pharmaceutical Preparations Industry

57th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Unity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Unity Biotechnology has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.00% of the float of Unity Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Unity Biotechnology has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Unity Biotechnology has recently increased by 5.35%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Unity Biotechnology does not currently pay a dividend.
Dividend Growth
Unity Biotechnology does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Unity Biotechnology has received a 74.69% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Unity Biotechnology is -0.60.

1.8

News and Social Media Coverage

News Sentiment
Unity Biotechnology has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Unity Biotechnology this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,023.00 in company stock.
Percentage Held by Insiders
Only 4.90% of the stock of Unity Biotechnology is held by insiders.
Percentage Held by Institutions
Only 29.49% of the stock of Unity Biotechnology is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Unity Biotechnology are expected to grow in the coming year, from ($2.66) to ($1.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unity Biotechnology is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unity Biotechnology is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Unity Biotechnology has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Unity Biotechnology Stock (NASDAQ:UBX)

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

UBX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

UBX Stock News Headlines

April 18, 2024 | americanbankingnews.com

Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)

April 17, 2024 | americanbankingnews.com

Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $8.00 by Analysts at HC Wainwright

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 15, 2024 | investorplace.com

UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023

April 15, 2024 | globenewswire.com

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

April 9, 2024 | finance.yahoo.com

Unity Biotechnology, Inc. (0YC0.L)

February 17, 2024 | finance.yahoo.com

UBX Mar 2024 2.000 call

February 7, 2024 | uk.investing.com

Unity Biotechnology Inc (UBX)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 6, 2024 | finance.yahoo.com

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

December 29, 2023 | finance.yahoo.com

10 Supplements for Longevity and Antiaging: Expert Recommendations

December 12, 2023 | finance.yahoo.com

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

November 27, 2023 | msn.com

Unity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63

November 17, 2023 | msn.com

Wedbush Upgrades Unity Biotechnology (UBX)

November 16, 2023 | msn.com

Wedbush upgrades Unity Biotechnology to outperform, cites cash runway

November 16, 2023 | finance.yahoo.com

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

November 15, 2023 | markets.businessinsider.com

Unity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy Rating

November 14, 2023 | finanznachrichten.de

Unity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

November 14, 2023 | msn.com

Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16

November 13, 2023 | tmcnet.com

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

November 13, 2023 | finance.yahoo.com

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

November 10, 2023 | msn.com

UNITY Biotechnology to exercise warrants for $4.38M in gross proceeds

November 10, 2023 | finance.yahoo.com

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

October 25, 2023 | finance.yahoo.com

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks

October 3, 2023 | finance.yahoo.com

20 Foods Consumed By Longest Living People Every Day

September 28, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Unity Biotechnology (UBX) and Rockwell Med (RMTI)

September 27, 2023 | markets.businessinsider.com

UNITY Biotechnology Reports Encouraging Results From Phase 2 ENVISION Study Of UBX1325

See More Headlines

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:UBX
CUSIP: N/A
CIK: 1463361
Web: www.unitybiotechnology.com
Phone: (650) 416-1192
Fax: N/A
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $8.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +300.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -88.92%
Return on Assets: -45.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.74
Quick Ratio: 5.74

Sales & Book Value

Annual Sales: $240,000.00
Price / Sales: 104.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.71 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 16,790,000
Free Float: 15,963,000
Market Cap: $25.19 million
Optionable: Optionable
Beta: 0.87

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Anirvan Ghosh Ph.D. (Age 60)
CEO & Director
Comp: $1.08M
Dr. Nathaniel E. David A.B. (Age 56)
Ph.D., Co-Founder & Executive Director
Comp: $40k
Ms. Lynne Marie Sullivan (Age 57)
CFO & Head of Corporate Development
Comp: $730.82k
Dr. Jan M. van Deursen
Founder
Dr. Judith Campisi Ph.D.
Founder
Mr. Daohong Zhou M.D.
Founder
Mr. Nathan Guz Ph.D.
Vice President of Operations
Mr. Alexander Azoy (Age 48)
Chief Accounting Officer & Principal Accounting Officer
Dr. Przemyslaw Sapieha Ph.D.
Chief Scientist
Mr. Alexander Hieu Nguyen J.D. (Age 47)
General Counsel & Corporate Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

UBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UBX shares.
View UBX analyst ratings or view top-rated stocks.
What is Unity Biotechnology's stock price target for 2024?: 2 brokerages have issued twelve-month target prices for Unity Biotechnology's stock. Their UBX share price targets range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 297.4% from the stock's current price.
View analysts price targets for UBX or view top-rated stocks among Wall Street analysts.
How have UBX shares performed in 2024?: Unity Biotechnology's stock was trading at $1.93 at the beginning of 2024. Since then, UBX stock has decreased by 21.8% and is now trading at $1.51.
View the best growth stocks for 2024 here.
When is Unity Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our UBX earnings forecast.
How were Unity Biotechnology's earnings last quarter?: Unity Biotechnology, Inc. (NASDAQ:UBX) posted its earnings results on Wednesday, November, 10th. The company reported ($3.00) earnings per share for the quarter, topping analysts' consensus estimates of ($3.60) by $0.60.

When did Unity Biotechnology's stock split?: Unity Biotechnology shares reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Unity Biotechnology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).
When did Unity Biotechnology IPO?: Unity Biotechnology (UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.
How do I buy shares of Unity Biotechnology?: Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UBX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Unity Biotechnology (UBX) Stock Price, News & Analysis

Unity Biotechnology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Unity Biotechnology Stock (NASDAQ:UBX)

UBX Stock Price History

UBX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

UBX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™